<DOC>
	<DOC>NCT00959036</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.</brief_summary>
	<brief_title>Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Clinical diagnosis of active rheumatoid arthritis on a stable background of methotrexate (7.525 mg weekly). Any significant health problem other than rheumatoid arthritis Any clinically significant laboratory abnormalities Any prior use of B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>